Proteome Sciences plc (AIM:PRM)
London flag London · Delayed Price · Currency is GBP · Price in GBX
3.040
-0.200 (-6.17%)
Jul 28, 2025, 4:35 PM GMT+1

Proteome Sciences Company Description

Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally.

The company offers TMT LC-MS2, a standard method for analyzing cells and tissues when no phosphopeptide enrichment is required; TMT LC-MS3, a standard method for biomarker discovery in plasma and other samples where quantitative accuracy is a factor; SysQuant that provides an analysis of protein activity across regulatory and signaling pathways; and TMTcalibrator which analyzes where diseased or treated tissue can be analyzed in parallel with peripheral fluids.

It also offers top 14 and top 65 super depletion of proteins from serum and plasma; selective reaction monitoring (SRM) and parallel reaction monitoring (PRM) based biomarker assay development; SRM assay, a targeted mass spectrometry assay format for the routine measurement of biomarkers; and TMT SRM, a targeted assay format that enables the rapid validation of biomarker candidates.

The company serves its products to pharmaceutical and biotechnology companies, as well as to academic research institutes.

The company was incorporated in 1993 and is based in Cobham, the United Kingdom.

Proteome Sciences plc
CountryUnited Kingdom
Founded1993
IndustryMedical - Diagnostics & Research
SectorHealthcare
Employees36
CEOMariola Sohngen

Contact Details

Address:
Coveham House
Cobham, KT11 3EP
United Kingdom
Phone44 20 7043 2116
Websiteproteomics.com

Stock Details

Ticker SymbolPRM
ExchangeLondon Stock Exchange AIM
Fiscal YearJanuary - December
Reporting CurrencyGBP
ISIN NumberGB0003104196
SIC Code8731

Key Executives

NamePosition
Mariola SohngenChief Executive Officer
Abdelghani OmariChief Financial Officer